Buy Idacio (adalimumab-aacf)

What is Idacio (adalimumab-aacf) for?

Idacio (adalimumab-aacf) is an adalimumab biosimilar medicine. It’s prescribed for the treatment of: Rheumatoid arthritis Juvenile idiopathic arthritis Psoriatic arthritis Ankylosing spondylitis Crohn’s disease Ulcerative colitis Plaque psoriasis^[1].

Idacio is administered as a subcutaneous injection and is available in a 40 mg/ 0.8 mL presentation^[4].

How does Idacio (adalimumab-aacf) work?

Idacio’s active ingredient, adalimumab, is a monoclonal antibody. It targets and binds to the tumour necrosis factor (TNF) in the body. TNF is considered to cause the inflammations experienced by patients with the diseases Idacio aims to treat. When adalimumab binds with TNF, it blocks its activity. As a result, it reduces inflammation and alleviates other symptoms of the diseases^[3].

Where has Idacio (adalimumab-aacf) been approved?

Idacio (adalimumab-aacf) is currently approved in:

• USA^[2]
• EU ^[3]
• Australia^[5]
• Canada^[6].

References:

1. About Idacio. Idacio, Acceessed 20 July 2023.
2. FDA Approves Idacio, the Eighth Adalimumab Biosimilar. Center for Biosimilars, December 2022.
3. Idacio | European Medicines Agency. European Medicines Agency, Accessed 20 July 2023.
4. Highlights of Prescribing Information. FDA, Accessed 20 July 2023.
5. AusPAR: Adalimumab. Therapeutic Goods Administration (TGA), September 2020.
6. Summary Basis of Decision – Idacio. Health Canada, Accessed 20 July 2023.